BIOSECURE Act 2026: How Peptide CDMOs Are Navigating the China Supply Chain Shift

The BIOSECURE Act, signed into law as part of the FY2026 National Defense Authorization Act in December 2025, is now moving from legislative text into operational reality for peptide manufacturers and their clients. With the Office of Management and Budget (OMB) expected to publish the definitive list of restricted biotechnology companies of concern in late 2026, the compliance clock is running, and every biopharma company that relies on Chinese contract development and manufacturing organizations for peptide active pharmaceutical ingredient production is either already executing a supply chain transition or falling dangerously behind.

The implications for the peptide industry are substantial. Peptide APIs and intermediates represent a meaningful share of the volume manufactured at major Chinese CDMOs, including WuXi STA, the peptide-focused subsidiary of WuXi AppTec. WuXi AppTec has already appeared on the Pentagon's Section 1260H list of companies with alleged Chinese military ties, a listing that has accelerated client departures even before formal BIOSECURE restrictions take effect.

What the BIOSECURE Act Does

The BIOSECURE Act bars U.S. federal procurement contracts, grants, and loans from being used to pay for biotechnology equipment or services provided by companies designated as "biotechnology companies of concern." The initial list of named companies includes WuXi AppTec, WuXi Biologics, BGI Genomics, MGI Tech, and Complete Genomics, but the statute authorizes OMB to add companies through a formal designation process, and the list is expected to expand.

For biopharma companies that receive federal grants (including NIH, BARDA, and DARPA funding), the law creates a direct compliance obligation: using BIOSECURE-restricted CDMOs in federally-funded work is prohibited. For commercially-funded work, the restriction is indirect but economically significant, major pharmaceutical companies and institutional investors are applying their own standards that go beyond the strict statutory requirement, effectively treating the BIOSECURE designation as a market-access barrier regardless of federal funding status.

The Scale of Chinese CDMO Dependence

Industry surveys conducted in early 2026 estimate that approximately 79% of biopharma companies have some level of dependence on Chinese CDMOs for API manufacturing, with peptide synthesis representing a significant subset. WuXi STA alone is estimated to manufacture peptide APIs for hundreds of programs globally, ranging from early-stage research supplies to commercial-scale GMP production.

The breadth of this dependence reflects two decades of cost-driven outsourcing. Chinese CDMOs achieved scale advantages in synthetic peptide manufacturing through investments in large-scale solid-phase peptide synthesis (SPPS) infrastructure, solvent recovery systems, and analytical capabilities that matched or exceeded Western alternatives at 30-50% lower cost. WuXi STA, Hybio Pharmaceutical, SciSparc, and Amide Pharma built dominant positions in this market over the 2010s. Unwinding that dependence requires not just finding alternative suppliers but validating them at GMP standards, a process that typically takes 18-36 months.

Where the Volume Is Going: India and South Korea Lead

The primary beneficiaries of the BIOSECURE-driven supply chain shift in the peptide space are India-based and South Korean CDMOs, which have both the technical capability and the capacity to absorb redirected volume.

India is the most significant near-term winner. The Indian peptide CDMO market, which had already been growing at high single-digit rates, is now tracking for substantially accelerated growth as Chinese orders shift. Companies including Piramal Pharma Solutions, Laurus Labs, and Divi's Laboratories have all been actively expanding SPPS capacity in anticipation of demand. The India-based CDMO market in peptides is estimated at approximately $2.4 billion currently, with projections to $6.9 billion by 2030 under the accelerated BIOSECURE scenario. Indian manufacturers benefit from lower cost structures than Western European or North American alternatives, a large trained chemistry workforce, and an established track record with FDA and EMA inspections.

South Korea offers a different value proposition: a cluster of highly capable mid-size CDMOs, Bachem Korea, Huons Peptide, Celltrion, and several smaller specialists, with strong track records in GLP-1 peptide synthesis and purification. South Korean facilities have benefited enormously from the GLP-1 manufacturing surge over the past two years, and they are positioned as the preferred alternative supplier for GLP-1 APIs where quality credentials at commercial scale are non-negotiable.

Western European CDMOs, led by Bachem (Switzerland), PolyPeptide Group (Sweden/Denmark/France), and Almac Group (UK), are seeing increased interest for programs where regulatory risk or supply security concerns justify higher cost of goods. Several EU-based CDMOs have announced capacity expansions specifically targeting the BIOSECURE-displaced volume. Their cost disadvantage relative to India is real but manageable for high-value, late-stage peptide drug products where margin is sufficient to absorb it.

North America is also expanding capacity, but domestic peptide CDMO capacity remains limited relative to global demand. New SPPS manufacturing facilities take 3-5 years to build and qualify, meaning the near-term domestic capacity expansion is insufficient to absorb Chinese volume even with accelerated investment. CSL Seqirus's manufacturing expansion in Holly Springs, North Carolina, and selected capacity additions at PolyPeptide's San Diego facility represent incremental additions, not step-change supply replacement.

Compliance Timeline Pressure

The OMB designation list, expected in Q4 2026, will establish definitive compliance obligations. Companies that wait for the list before beginning supply chain transitions will find themselves competing for limited alternative CDMO capacity alongside hundreds of other displaced clients, and facing significantly higher contract pricing as demand outstrips supply.

CDMO rates at alternative suppliers are already reflecting the capacity pressure. Industry pricing data from Q2 2026 indicates that peptide API manufacturing rates at Indian and South Korean CDMOs have increased 5-10% year-over-year, with lead times for GMP batch initiation extending from 12 to 18+ weeks at some facilities. Companies that signed multi-year capacity agreements in 2025 or early 2026 are in substantially better competitive positions than those still evaluating options.

The supply chain transition also creates compliance staffing demands. Companies need regulatory affairs specialists experienced in CMC submissions to manage the technical package updates required when a manufacturing site change is filed with FDA (a Prior Approval Supplement or CBE-30 depending on the drug development stage). They need quality assurance managers who can lead the supplier qualification audits at new CDMO sites. And they need supply chain strategists who can model dual-source scenarios and manage the inventory buffer periods required during transitions.

Strategic Considerations for Peptide Companies

The BIOSECURE transition is not just a compliance exercise, it is a strategic realignment that will reshape the competitive landscape for peptide manufacturing. Companies that treat it purely as a cost and logistics problem will solve the immediate compliance issue while missing the broader opportunity.

The companies that are moving fastest are using the forced transition as an opportunity to diversify their sourcing to two or three qualified suppliers, reducing single-source dependency that predated BIOSECURE. They are also exploring vertical integration, particularly for GLP-1 APIs, where the manufacturing volumes and commercial stakes are large enough to justify in-house peptide synthesis capability.

For clinical-stage companies whose programs are funded by BARDA, NIH, or other federal sources, the compliance timeline is non-negotiable. Federal funding agreements are already including BIOSECURE compliance representations, and agencies are auditing manufacturing supply chains in the pre-award process.

The message from the regulatory and legal landscape is unambiguous: the BIOSECURE Act is law, enforcement is coming, and the window to execute supply chain transitions before capacity constraints and compliance deadlines coincide is closing.

Related coverage on PeptideStaff: Asia-Pacific peptide manufacturing growth, China peptide CDMO risk analysis, peptide CDMO North America expansion, BioSecure Act supply chain impact.